Referencias Bibliográficas
Sistema Endocanabinoide:
Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis and Cannabinoid Research. 2016.
Rey, A.A. et al. Biphasic Effects of Cannabinoids in Anxiety Responses: CB1 and GABAB Receptors in the Balance of GABAergic and Glutamatergic Neurotransmission. Neuropsychopharmacology, 1-11, 2012
Efeito Entourage:
Koltai H, Namdar D. Cannabis Phytomolecule ‘Entourage’: From Domestication to Medical Use. Trends Plant Sci. 2020;25(10):976-984. doi:10.1016/j. tplants.2020.04.007
Kapinová, Andrea, Patrik Štefanička, Peter Kubatka, Pavol Žúbor, Sona Uramova, Martin Kello, Ján Mojžiš, Dana Blahútová, Tawar Qaradakhi, Anthony Zulli, M. Caprnda, Ján Danko, Zora Lasabová, Dietrich Büsselberg and Peter Kruzliak. “Are plant-based functional foods better choice against cancer than single phytochemicals? A critical review of current breast cancer research.” Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2017(96):1465-1477. doi:10.1016/j.biopha.2017.11.134
Rey AA, Purrio M, Viveros MP, Lutz B. Efeitos bifásicos dos canabinóides nas respostas de ansiedade: receptores CB1 e GABA(B) no equilíbrio da neurotransmissão GABAérgica e glutamatérgica. Neuropsicofarmacologia. 2012;37(12):2624-2634. doi:10.1038/npp.2012.123
Maayah ZH, Takahara S, Ferdaoussi M, Dyck JRB. The anti-inflammatory and analgesic effects of formulated full-spectrum cannabis extract in the treatment of neuropathic pain associated with multiplesclerosis. Inflamm Res. 2020;69(6):549-558. doi:10.1007/s00011-020-01341-1
Booth JK, Bohlmann J. Terpenes in Cannabis sativa – From plant genome to humans. Plant Sci. 2019;284:67-72. doi:10.1016/j.plantsci.2019.03.022
McPartland, JM., Russo, EB. Cannabis and cannabis extracts:greater than the sum of their parts? J. Cannabis Therap. 2001. 1 (3–4),103–132
Gerritsen ME, Carley WW, Ranges GE, et al. Flavonoids inhibit cytokine-induced endothelial cell adhesion protein gene expression. Am J Pathol. 1995;147(2):278-292.
Salgueiro JB, Ardenghi P, Dias M, et al. Anxiolytic natural and synthetic fl avonoid ligands of the central benzodiazepine receptor have no effect on memory tasks in rats. Pharmacol Biochem Behav. 1997;58(4):887-91.
Barrett, ML., Scutt, AM., Evans, FJ. Cannfl avin A and B, prenylated fl avones from Cannabis sativa L. Experientia. 1982;42(4), 452–453.
THC Permitido:
Delgado-Povedano, M.M. et al. Untargeted characterization of extracts from Cannabis sativa L. cultivars by gas and liquid chromatography coupled to mass spectrometry in high resolution mode.Talanta, 2019.
Honório, K.M.; Arroio, A.; da Silva, A.B.F. ASPECTOS TERAPÊUTICOS DE COMPOSTOS DA PLANTA Cannabis sativa. Quim. Nova, Vol. 29, No. 2, 318-325, 2006
UNODC – United Nations Offi ce on Drugs and Crimes (2009) Recommended methods for the identifi cation and analysis of cannabis and cannabis products. Manual for use by national drug analysis laboratories. United Nations, New York. 60p.
Cerino P, Buonerba C, Cannazza G, D’Auria J, Ottoni E, Fulgione A, Di Stasio A, Pierri B, Gallo A (2020) A review of hemp as food and nutritional supplement, Cannabis and Cannabinoid Research X:X, 1–9, DOI: 10.1089/can.2020.0001.
Marinotti O, Sarill M. Differentiating Full-Spectrum Hemp Extracts from CBD Isolates: Implications for Policy, Safety and Science. J Diet Suppl. 2020;17(5):517- 526. doi:10.1080/19390211.2020.1776806
Broad Spectrum Isolado:
Uziel A, Gelfand A, Amsalem K, et al. Full-Spectrum Cannabis Extract Microdepots Support Controlled Release of Multiple Phytocannabinoids for Extended Therapeutic Effect. ACS Appl Mater Interfaces. 2020;12(21):23707-23716. doi:10.1021/acsami.0c0443
Russo EB. 2019. The case for the entourage effect and conventional breeding of clinical cannabis: no “strain”. No Gain. Front Plant Sci. 9:1969.
Pamplona FA, da Silva LR, Coan AC. 2018. Potential clinical benefits of CBD-rich cannabis extracts over purifiedcbd in treatment-resistant epilepsy: observational data meta-analysis. Front Neurol. 9:759.
Fitofármaco e fitoterápico:
Agência Nacional de Vigilância Sanitária (ANVISA). Resolução da Diretoria Colegiada – RDC n° 327, de 11 de dezembro de 2019, Dispõe sobre os procedimentos para a concessão da Autorização Sanitária para a fabricação e a importação, bem como estabelece requisitos para a comercialização, prescrição, a dispensação, o monitoramento e a fiscalização de produtos de Cannabis para fins medicinais, e dá outras providências. Diário Oficial da União, Poder Executivo, Brasília.
Agência Nacional de Vigilância Sanitária (ANVISA). Resolução da Diretoria Colegiada – RDC n° 26, de 13 de maio de 2014, Dispõe sobre o registro de medicamentos fitoterápicos e o registro e a notificação de produtos tradicionais fitoterápicos. Diário Oficial da União, Poder Executivo, Brasília.
Agência Nacional de Vigilância Sanitária (ANVISA). Resolução da Diretoria Colegiada – RDC n° 24, de 14 de junho de 2010, Dispõe sobre o registro de medicamentos específicos. . Diário Oficial da União, Poder Executivo, Brasília
Sono e cannabis:
Chokroverty S. Overview of sleep & sleep disorders. Indian J Med Res.;131:126-40, 2010.
Gomes MM, Quinhones MS, Engelhardt E. Neurofisiologia do sono e aspectos farmacoterapêuticos dos seus transtornos [revisão]/Neurophysiology of sleep and pharmacotherapeutic aspects of their disorders: [review]. Rev Bras Neurol. 46(1):5-15, 2010.
Rodrigues MH, Ramalheira J, Lopes J, et al. Polissonografi a:aspectos técnicos e clínicos. Rev Bras Neurol. 2012;48(1/2):7-23.
Shahveisi K. et a. Novel object recognition memory in REM sleep-deprived rats: Role of the cannabinoid CB1 receptor. Behavioural Brain Research. 381, 112311, 2020.
Nicholson AN, Turner C, Stone BM, Robson PJ. Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol. 2004;24(3):305-313. doi:10.1097/01.jcp.0000125688.05091.8f
Chagas MH, Crippa JA, Zuardi AW, et al. Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. J Psychopharmacol. 2013;27(3):312-316. doi:10.1177/0269881112474524
Ansiedade e cannabis:
Balderston, N.L. Mechanistic link between right prefrontal cortical activity and anxious arousal revealed using transcranial magnetic stimulation in healthy subjects. Nature: Neuropsychopharmacology, 2020.
Grillon, C. et al. Modeling anxiety in healthy humans: a key intermediate bridge between basic and clinical sciences. Nature: Neuropsychopharmacology, 2019.
Brooks, S.J. A systematic review of the neural bases of psychotherapy for anxiety and related disorders. Dialogues in Clinical Neuroscience .17,. 3 , 2015.
Babaev, O. Inhibition in the amygdala anxiety circuitry. Experimental & Molecular Medicine. 50:18, 2018.
Botsford, S.L. et al. Review: Cannabis and Cannabinoids in Mood and Anxiety Disorders: Impact on Illness Onset and Course, and Assessment of Therapeutic Potential. Am J Addict. 29, 1, 9–26, 2021.
Ferber, S.G. The “Entourage Effect”: Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders. Current Neuropharmacology. 18, 87-96, 2020.
Shannon, S.M.D. et al. Cannabidiol in Anxiety and Sleep: A Large Case Series. The Permanente Journal. 23, 10-041, 2019.
Zuardi AW, Rodrigues NP, Silva AL, et al. Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life. Front Pharmacol. 2017;8:259. Published 2017 May 11. doi:10.3389/fphar.2017.00259
Linares IM, Zuardi AW, Pereira LC, et al. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Braz J Psychiatry. 2019;41(1):9-14. doi:10.1590/1516-4446-2017-0015
Depressão e cannabis:
Perito, M.E.S. & Fortunato, J.J. Biological Markers of Depression: A Review on the Expression of Neurotrophic Factors. Rev Neurocienc 2012
Boku, S., Nakagawa, S., Toda, H., and Hishimoto, A. (2018). Neural basis of major depressive disorder: beyond monoamine hypothesis. Comput. Graph. Forum
Nobis, A. et al. Peripheral Markers of Depression. J. Clin. Med. 9, 3793, 2020.
Maes, M. & Carvalho, A.F. . The compensatory immune-regulatory refl ex system (CIRS) in depression and bipolar disorder. Mol. Neurobiol. 55, 8885–8903, 2018.
El-Alfy, A. T. et al. Antidepressant-like effect of ∆9-tetrahydrocannabinol and Other cannabinoids isolated from Cannabis sativa L. Pharmacol Biochem Behav.
Suryavanshi, S.V. et al. Cannabinoids as Key Regulators of Infl ammasome Signaling: A Current Perspective. Front. Immunol., 28, 2021.
Mecha M, Feliu A, Inigo PM, Mestre L, Carrillo-Salinas FJ, Guaza C. Cannabidiol provides long-lasting protection against the deleterious effects of infl ammation in a viral model of multiple sclerosis: a role for A2A receptors. Neurobiol Dis (2013)
Greineisen, W. E. & Turner, H. Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists. Int Immunopharmacol. 2010.
Martin EL, Strickland JC, Schlienz NJ, et al. Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial. Front Psychiatry. 2021;12:729800. Published 2021 Sep 9. doi:10.3389/fpsyt.2021.729800
Enxaqueca e cannabis:
Donato et al.Sinapse Journal: Where Are We and Where Do We Intend to Go?. Sinapse, vol. 20, 4, 2020.
Vicent, M.B. Fisiopatologia da Enxaqueca. Arq. Neuropsiquiatr, 56, 4, 841-851, 1998.
Duarte C. The analgesic potential of cannabinoids. Revista SPA, v.21, 3, 2012.
Mlost J. et al. Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action. Int. J. Mol. Sci. 21, 8870, 2020.
Lochte B.C. et al. The Use of Cannabis for Headache Disorders. Cannabis Cannabinoid Res. 2(1): 61–71, 2017.
Baron EP. Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefi ts in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science. Headache. 2018;58(7):1139-1186. doi:10.1111/head.13345
